Mayo Clinic

View All

pharma-news
Merck supports Peloton Therapeutics; Thermo Fisher, WuXi and Mayo Clinic join hands; JNJ’s anti-BCMA CAR-T sweeps multiple myeloma aside; Tafinlar-Mekinist combo of Novartis receives a boost

Merck supports Peloton Therapeutics with positive kidney cancer data Merck is revealing the data from a phase 2 study of a HIF-2α inhibitor after a year betting USD 1.05 billion on Peloton Therapeutics, and the deal is promising.  The drug limited tumour growth in 43% and shrank tumors in 28% of patients...

Find More